Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study
Frontiers in Oncology · 30.06.2026 · 16
DOI: 10.3389/fonc.2026.1883224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 30.06.2026. Verfasst von Tao Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
PSA screening has limited specificity in the 10–20 ng/mL range, making biopsy decisions difficult. Metabolic disorders and inflammation may improve risk prediction. We aimed to develop a model integrating multidimensional indicators to predict prostate cancer and high−grade disease in men with tPSA >10 ng/mL.
Methods
This retrospective study included 461 men who underwent prostate biopsy (tPSA >10 ng/mL). Patients were randomly split into training (70%) and validation (30%) sets. Two logistic regression models were built: Model 1 for benign vs. malignant; Model 2 (in malignant cases) for high−grade (ISUP ≥3) vs. low−grade. Variables with VIF>5 were excluded. Backward stepwise (AIC) and univariate P < 0.05 guided variable selection. Performance was assessed by AUC, calibration, DCA, and compared with fPSA% alone using DeLong test.
Result
Among 461 patients, 252 (54.7%) had prostate cancer, and 139 (55.2% of malignant cases) had high−grade disease. Malignant patients were older, had higher BMI, TyG index, NLR, and tPSA, and lower fPSA% (all P < 0.05). High−grade patients showed similar metabolic differences but no tPSA difference versus low−grade. Model 1 retained age, TyG index, NLR, fPSA%, smoking, hypertension, and lesion location. Model 2 retained age, TyG index, LDH, and smoking history. Validation AUC was 0.871 for Model 1 and 0.779 for Model 2. At optimal thresholds, sensitivity/specificity were 80.3%/74.6% (Model 1) and 71.7%/62.1% (Model 2). Both models showed good calibration (Hosmer−Lemeshow P>0.05). Decision curve analysis and DeLong test confirmed that each full model provided higher net benefit than fPSA% alone ( P < 0.05).
Conclusion
Two nomograms using routine clinical and laboratory variables may assist in risk stratification for prostate cancer and high−grade disease in men with tPSA >10 ng/mL, outperforming fPSA% alone. These tools can help reduce unnecessary biopsies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
- West China School of Medicine and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
- Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Zitieren
APA
Zhang, T., Li, X., Zeng, J., Xu, M., & Tie, Y. (2026). Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1883224
Vancouver
Zhang T, Li X, Zeng J, Xu M, Tie Y. Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1883224
BibTeX
@article{Zhang2026,
author = {Zhang, Tao and Li, Xue and Zeng, Junsong and Xu, Maosen and Tie, Yan},
title = {Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1883224}
}
EUVIMED